Vertex Pharmaceuticals (VRTX) reachead $495.29 at the closing of the latest trading day, reflecting a +1.42% change compared to its last close.

Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...

Vertex Pharmaceuticals’ triple combination cystic fibrosis (CF) treatment has been approved by the Medicines and Healthcare ...

For current and former smokers, statins may reduce the amount of chest muscle loss, while aspirin may contribute to increased chest muscle loss, according to a new study.

Google Cloud's Vertex AI Search for Healthcare tool is designed to make it faster for healthcare professionals and other ...

There are few signs the industry responsible for more than 115,000 Massachusetts jobs is pulling out of its four-year downswing.

In the Boston area, three months into the new year, the mood in the biotech industry has soured and the outlook has clouded.

UK MHRA approves Vertex’s Alyftrek, a once-daily next-in-class CFTR modulator to treat cystic fibrosis: London Monday, March 10, 2025, 10:00 Hrs [IST] Vertex Pharmaceuticals, a ...

Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” fourth quarter 2024 ...

The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...